Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Provides Comment on Impact of Vascepa® Patent Litigation on MAT9001 and Update on COVID-19 Pandemic’s Effect on Business Operations and Clinical Programs

BEDMINSTER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on the recent United States...
March 09, 2020 06:30 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights

Initiated ENHANCE-IT study of MAT9001 against Vascepa®. Topline data expected Q4 2020 Initiated efficacy phase of NIH-funded EnACT study of MAT2203 in cryptococcal meningitis Q1 2020 Management to...
March 05, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Initiation of ENHANCE-IT Study of MAT9001 Against Vascepa®

– Topline data expected Q4 2020 – BEDMINSTER, N.J., March 05, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has initiated the ENHANCE-IT Study...
March 04, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Appoints James A. Underberg, M.D. to its MAT9001 Scientific Advisory Board

BEDMINSTER, N.J., March 04, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB) today announced the appointment of James A. Underberg, M.D., M.S., FACPM, FACP, FNYAM, FASPC,...
February 24, 2020 16:15 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Webcast Conference Call Discussing Fourth Quarter and Full Year 2019 Operational and Financial Results on March 9, 2020

BEDMINSTER, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today...
February 19, 2020 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces DSMB Approval to Commence Part 2 of EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

– Part 2 efficacy portion of EnACT expected to commence Q1 2020 – BEDMINSTER, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that the...
January 14, 2020 11:21 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Closing of Public Offering of Common Stock

BEDMINSTER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today...
January 10, 2020 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Pricing of Public Offering of Common Stock

BEDMINSTER, N.J., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today...
January 09, 2020 16:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Proposed Public Offering of Common Stock

BEDMINSTER, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today...
December 12, 2019 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform

BEDMINSTER, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a member of...